71432-55-8

Basic information

• Product Name: 2-TERT-BUTYL-1,3-DIISOPROPYLISOUREA
• Synonyms: 2-TERT-BUTYL-1,3-DIISOPROPYLISOUREA;tert-Butyl N,N'-diisopropylcarbaMiMidate;CarbaMiMidic acid, N,N'-bis(1-Methylethyl)-, 1,1-diMethylethyl ester;O-tert-Butyl-N,N'-diisopropylisourea;tert-butyl N,N'-bis(1-methylethyl)imidocarbamate;tert-Butyl N,N'-diisopropylimidocarbamate
• CAS NO: 71432-55-8
• Molecular Formula: C₁₁H₂₄N₂O
• Molecular Weight: 200.32
• Mol File: 71432-55-8.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 61°C/10mmHg(lit.)
• Flash Point: 134.87 °C
• Appearance: /
• Density: 0.891 g/cm³
• Refractive Index: 1.4240-1.4280
• Storage Temp.: 0-10°C
• PKA: 9.54±0.50(Predicted)
• CAS DataBase Reference: 2-TERT-BUTYL-1,3-DIISOPROPYLISOUREA(CAS DataBase Reference)
• NIST Chemistry Reference: 2-TERT-BUTYL-1,3-DIISOPROPYLISOUREA(71432-55-8)
• EPA Substance Registry System: 2-TERT-BUTYL-1,3-DIISOPROPYLISOUREA(71432-55-8)

Safety Data

• Hazardous Substances Data: 71432-55-8(Hazardous Substances Data)

Usage

Physical Form

liquid

Uses

2-tert-Butyl-1,3-diisopropylisourea is a useful synthetic intermediate in the synthesis of 5-Oxo Atorvastatin tert-Butyl Ester (O847160) which is a Boc-protected derivative of Atorvastatin. 2-tert-Butyl-1,3-diisopropylisourea is also used as a reagent in the total synthesis of Citrafungin A which is an antifungal natural product.

Upstream product

• 100-43-6 4-vinylpyridine 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 185155-24-2 (1S,3S,4S,5R,6R,7R)-6,7-Bis-benzyloxy-1-but-3-enyl-4-hydroxy-4-vinyl-2,8-dioxa-bicyclo[3.2.1]octane-3,5-dicarboxylic acid di-tert-butyl ester 
• 185155-19-5 (1S,3S,4R,5R,6R,7R)-6,7-Bis-benzyloxy-1-but-3-enyl-4-hydroxy-4-(5-methyl-furan-2-yl)-2,8-dioxa-bicyclo[3.2.1]octane-3,5-dicarboxylic acid di-tert-butyl ester 
• 185155-27-5 (1S,3S,4S,5R,6R,7R)-6,7-Bis-benzyloxy-1-[3-(tert-butyl-dimethyl-silanyloxy)-propyl]-4-hydroxy-2,8-dioxa-bicyclo[3.2.1]octane-3,4,5-tricarboxylic acid tri-tert-butyl ester 
• 182485-46-7 (S)-3-((2R,3R,4R,5S,6R)-4,5-Diacetoxy-6-acetoxymethyl-3-acetylamino-tetrahydro-pyran-2-yloxy)-2-(4-phenylacetoxy-benzyloxycarbonylamino)-propionic acid tert-butyl ester 
• 191935-35-0 tri(tert-butyl) [1S,1(4R,5R),3S,4S,5R,6R,7R]-1-(4-benzyloxy-5-methyl-6-phenylhexyl)-4,6,7-trihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylate 
• 207729-00-8 ethyl 1-((tert-butoxycarbonyl)amino)cyclopent-3-ene-1-carboxylate 
• 193751-54-1 tert-butyl cyclopent-3-en-1-ylcarbamate 
• 208338-39-0 (1S,3S,4S,5R,6R,7R,4'R,5'R)-1-[4'-acetoxy-5'-methyl-6'-phenylhex-1'-yl]-6,7-bis(benzoyloxy)-3,4,5-tris(2,2-dimethylpropionyl)-4-hydroxy-2,8-dioxabicyclo[3.2.1]octane 
• 326494-33-1 (2S,3S)-3-[(2R,3R,4S,5S)-5-Benzyloxymethyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-2-ethynyl-tetrahydro-furan-2-yl]-3-trimethylsilanylethynyl-1,4-dioxa-spiro[4.4]nonane-2-carboxylic acid tert-butyl ester 
• 326494-39-7 (2S,3S)-2-[(2R,3R,4S,5S)-5-Benzoyloxymethyl-2-tert-butoxycarbonyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-tetrahydro-furan-2-yl]-1,4-dioxa-spiro[4.4]nonane-2,3-dicarboxylic acid di-tert-butyl ester 
• 395098-94-9 (+/-)-tert-butyl 3-(4-hydroxyphenyl)lactate 
• 512196-74-6 4-(4-methoxybenzyloxy)butyric acid tert-butyl ester 
• 857732-40-2 (2R,3S,5R)-2-Allyl-5-methoxy-3-(4-methoxy-benzyloxy)-tetrahydro-furan-2-carboxylic acid tert-butyl ester 
• 146968-18-5 (1S,3S,4S,5R,6R,7R)-6-((E)-(4S,6S)-4,6-Dimethyl-oct-2-enoyloxy)-4-hydroxy-7-(1-methoxy-1-methyl-ethoxy)-1-((4S,5R)-5-methyl-3-methylene-6-phenyl-4-propylcarbamoyloxy-hexyl)-2,8-dioxa-bicyclo[3.2.1]octane-3,4,5-tricarboxylic acid tri-tert-butyl ester 

Relevant articles and documents

RADIOACTIVELY LABELED SUBSTANCE

Provided are: a radiolabeled drug, which is efficiently accumulated in a target and has high in vivo stability; and diagnosis and treatment each using the radiolabeled drug. Specifically provided are: a radiolabeled drug showing increased accumulation in a target site, which comprises a complex composed of a ligand that is bound to a compound capable of binding to a target molecule and forms a polycoordinated complex with a metal (e.g., technetium or rhenium) and a radionuclide of the metal; the radiolabeled drug for diagnosis or treatment; a ligand for preparing the radiolabeled drug; a kit that comprises a drug comprising the ligand and a drug comprising a radionuclide of a metal, as separate package units; and a method of increasing accumulation of a radiolabeled drug in a target site, comprising using the above-mentioned radiolabeled drug.